Mirati Therapeutics (NASDAQ: MRTX) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.
Insider & Institutional Ownership
59.5% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 20.4% of VBI Vaccines shares are held by institutional investors. 5.1% of Mirati Therapeutics shares are held by insiders. Comparatively, 34.1% of VBI Vaccines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent ratings for Mirati Therapeutics and VBI Vaccines, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mirati Therapeutics presently has a consensus price target of $14.14, indicating a potential downside of 8.76%. VBI Vaccines has a consensus price target of $10.00, indicating a potential upside of 138.10%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Mirati Therapeutics.
Volatility & Risk
Mirati Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500.
This table compares Mirati Therapeutics and VBI Vaccines’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Mirati Therapeutics and VBI Vaccines’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Mirati Therapeutics||N/A||N/A||-$83.11 million||($3.11)||-4.98|
|VBI Vaccines||$550,000.00||487.28||-$23.20 million||N/A||N/A|
VBI Vaccines has higher revenue and earnings than Mirati Therapeutics.
VBI Vaccines beats Mirati Therapeutics on 8 of the 10 factors compared between the two stocks.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
VBI Vaccines Company Profile
VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.